(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Also, the company is yet to record revenues from the sales of its sole-marketed product Casgevy, despite it being approved in early 2024. Shares of CRISPR Therapeutics have plunged 43% in the past ...

CRISPR Therapeutics (NASDAQ: CRSP) soared a couple of years ago as it brought Casgevy, its blood disorders treatment, from late-stage development to regulatory approval. This is the first approved ...

NY resident Sebastien Beauzile was treated with a pioneering new gene therapy approach called Lyfgenia, curing his sickle ...

And second, it opens the door to product revenue. It's important to keep in mind, though, that the rollout of Casgevy involves a months-long treatment process, so it will take time for revenue to ...